
Gregor S D Reid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6016700/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization. Journal of Immunology, 2004, 172, 1146-1156.	0.4	392
2	mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood, 2008, 112, 2020-2023.	0.6	117
3	Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing Journal of Experimental Medicine, 1994, 180, 1415-1425.	4.2	88
4	TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nature Biotechnology, 2000, 18, 515-520.	9.4	88
5	Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2007, 13, 386-397.	2.0	81
6	Primary Immunodeficiency to pneumococcal infection due to a defect in Toll-like receptor signaling. Journal of Pediatrics, 2004, 144, 512-518.	0.9	68
7	Targeting Notch signaling in autoimmune and lymphoproliferative disease. Blood, 2008, 111, 705-714.	0.6	68
8	Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood, 2011, 118, e112-e117.	0.6	49
9	CD47-ligation induced cell death in T-acute lymphoblastic leukemia. Cell Death and Disease, 2018, 9, 544.	2.7	49
10	In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood, 2007, 109, 2008-2013.	0.6	42
11	Novel Peptide-Binding Proteins and Peptide Transport in Normal and TAP-Deficient Microsomes. Biochemistry, 1997, 36, 856-863.	1.2	38
12	The role of the ovary and nutritional signals in the regulation of fat body yolk protein gene expression in Drosophila melanogaster. Journal of Insect Physiology, 1990, 36, 471-479.	0.9	36
13	CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood, 2005, 105, 3641-3647.	0.6	36
14	Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood, 2009, 114, 2459-2466.	0.6	36
15	Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease. Immunologic Research, 2008, 42, 84-105.	1.3	35
16	Intravenous immunoglobulin skews macrophages to an anti-inflammatory, IL-10-producing activation state. Journal of Leukocyte Biology, 2015, 98, 983-994.	1.5	32
17	Interferon-Â-Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo. Clinical Cancer Research, 2009, 15, 6602-6608.	3.2	30
18	Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	30

GREGOR S D REID

#	Article	IF	CITATIONS
19	ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. British Journal of Haematology, 2002, 116, 266-272.	1.2	26
20	Ulcerative Colitis-associated <i>E. coli</i> pathobionts potentiate colitis in susceptible hosts. Gut Microbes, 2020, 12, 1847976.	4.3	26
21	α-Integrin expression and function modulates presentation of cell surface calreticulin. Cell Death and Disease, 2016, 7, e2268-e2268.	2.7	25
22	Differential immune effects mediated by Toll-like receptors stimulation in precursor B-cell acute lymphoblastic leukaemia. British Journal of Haematology, 2005, 132, 051220022257006.	1.2	23
23	Expression of the adaptor protein BLNK/SLP-65 in childhood acute lymphoblastic leukemia. Leukemia, 2004, 18, 922-925.	3.3	21
24	Differential killing of pre-B acute lymphoblastic leukaemia cells by activated NK cells and the NK-92 ci cell line. Clinical and Experimental Immunology, 2002, 129, 265-271.	1.1	19
25	Integrins and ERp57 Coordinate to Regulate Cell Surface Calreticulin in Immunogenic Cell Death. Frontiers in Oncology, 2019, 9, 411.	1.3	18
26	Progression of spontaneous autoimmune diabetes is associated with a switch in the killing mechanism used by autoreactive CTL. International Immunology, 2004, 16, 1657-1662.	1.8	17
27	Heterodimerâ€specific TLR2 stimulation results in divergent functional outcomes in Bâ€cell precursor acute lymphoblastic leukemia. European Journal of Immunology, 2015, 45, 1980-1990.	1.6	15
28	The nonmotor adaptor HMMR dampens Eg5-mediated forces to preserve the kinetics and integrity of chromosome segregation. Molecular Biology of the Cell, 2018, 29, 786-796.	0.9	15
29	In Vivo Control of Acute Lymphoblastic Leukemia by Immunostimulatory CpG Oligonucleotides Blood, 2006, 108, 1868-1868.	0.6	15
30	Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways. European Journal of Pharmaceutical Sciences, 2022, 176, 106234.	1.9	14
31	IFNâ€Î³ directly inhibits murine Bâ€cell precursor leukemiaâ€initiating cell proliferation early in life. European Journal of Immunology, 2017, 47, 892-899.	1.6	13
32	PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways. Journal of Experimental and Clinical Cancer Research, 2021, 40, 96.	3.5	13
33	The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study. Pediatric Hematology and Oncology, 2019, 36, 468-481.	0.3	12
34	Altered patterns of T cell cytokine production induced by relapsed pre-B ALL cells. Leukemia Research, 2003, 27, 1135-1142.	0.4	11
35	HLA-DM expression is elevated in ETV6–AML1 translocation-positive pediatric acute lymphoblastic leukemia. Leukemia Research, 2006, 30, 487-489.	0.4	10
36	Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1β production. Cell Death and Disease, 2018, 9, 162.	2.7	10

GREGOR S D REID

#	Article	IF	CITATIONS
37	Heterodimer-Specific Stimulation Of Toll-Like Receptor 2 Induces Divergent Downstream Effects In Primary Samples Of Precursor B Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3918-3918.	0.6	9
38	Surrogate Antigen Processing Mediated by TAP-dependent Antigenic Peptide Secretion. Journal of Cell Biology, 1998, 140, 17-27.	2.3	8
39	Y-box-binding protein 1 contributes to IL-7-mediated survival signaling in B-cell precursor acute lymphoblastic leukemia. Oncology Letters, 2017, 13, 497-505.	0.8	8
40	Tumor Variant Identification That Accounts for the Unique Molecular Landscape of Pediatric Malignancies. JNCI Cancer Spectrum, 2018, 2, pky079.	1.4	8
41	TLR9 limits enteric antimicrobial responses and promotes microbiotaâ€based colonisation resistance during <i>Citrobacter rodentium</i> infection. Cellular Microbiology, 2019, 21, e13026.	1.1	8
42	Detection of T-Cells Specific for Leukemia-Associated Antigens in Pediatric Patients with Acute Lymphoblastic Leukemia in First Complete Remission Blood, 2004, 104, 526-526.	0.6	8
43	Immune evasion strategies of pediatric precursor-B acute lymphoblastic leukemia after allogeneic bone marrow transplantation—a case study. Leukemia Research, 2005, 29, 711-714.	0.4	7
44	Detection of WT1-specific T cells in paediatric acute lymphoblastic leukaemia patients in first remission. British Journal of Haematology, 2008, 141, 271-273.	1.2	6
45	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. Cancers, 2020, 12, 169.	1.7	5
46	ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. British Journal of Haematology, 2002, 116, 266-72.	1.2	3
47	A crossâ€standardized flow cytometry platform to assess phenotypic stability in precursor Bâ€cell acute lymphoblastic leukemia (Bâ€ALL) xenografts. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 57-71.	1.1	1
48	Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia. Blood, 2010, 116, 2140-2140.	0.6	1
49	MRD Xenotransplantation Prospectively Identifies Treatment-Selected Acute Lymphoblastic Leukemia Subpopulations with Relapse-Initiating Potential. Blood, 2020, 136, 12-13.	0.6	1
50	Stimulation of Precursor-B Acute Lymphoblastic Leukemia Cells with Toll-Like Receptor Ligands Alters Their Immunogenicity Blood, 2004, 104, 1887-1887.	0.6	0
51	CpG Oligonucleotides Induce Anti-Leukemia Activity in a Syngeneic Murine Model of Acute Lymphoblastic Leukemia Blood, 2007, 110, 2830-2830.	0.6	Ο
52	Removal of Normal Competition Increases Proliferation of Pre-Leukemic Cells in a Mouse Model of Pre-B Acute Lymphoblastic Leukemia Blood, 2009, 114, 1430-1430.	0.6	0
53	A Novel Model of Immune-Mediated Disease Equilibrium in Acute Lymphoblastic Leukemia. Blood, 2012, 120, 3540-3540.	0.6	0
54	Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3717-3717.	0.6	0

#	Article	IF	CITATIONS
55	Engraftment and Long-Term Survival at Low Burden of Leukemic Blasts from Primary MRD+ Human Bone Marrow in a Xenotransplant Setting. Blood, 2016, 128, 1730-1730.	0.6	Ο
56	Toll-like Receptor-3 Ligation Induces Pro-Survival Signaling in Pediatric Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3403-3403.	0.6	0